Y
Yoshihiko Kanno
Researcher at Tokyo Medical University
Publications - 201
Citations - 5095
Yoshihiko Kanno is an academic researcher from Tokyo Medical University. The author has contributed to research in topics: Blood pressure & Kidney disease. The author has an hindex of 34, co-authored 188 publications receiving 4166 citations. Previous affiliations of Yoshihiko Kanno include Saitama Medical University & Keio University.
Papers
More filters
Journal ArticleDOI
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Satoshi Umemura,Hisatomi Arima,Shuji Arima,Kei Asayama,Yasuaki Dohi,Yoshitaka Hirooka,Takeshi Horio,Satoshi Hoshide,Shunya Ikeda,Toshihiko Ishimitsu,Masaaki Ito,Sadayoshi Ito,Yoshio Iwashima,Hisashi Kai,Kei Kamide,Yoshihiko Kanno,Naoki Kashihara,Yuhei Kawano,Toru Kikuchi,Kazuo Kitamura,Takanari Kitazono,Katsuhiko Kohara,Masataka Kudo,Hiroo Kumagai,Kiyoshi Matsumura,Hideo Matsuura,Katsuyuki Miura,Masashi Mukoyama,Satoko Nakamura,Takayoshi Ohkubo,Yusuke Ohya,Takafumi Okura,Hiromi Rakugi,Shigeyuki Saitoh,Hirotaka Shibata,Tatsuo Shimosawa,Hiromichi Suzuki,Shori Takahashi,Kouichi Tamura,Hirofumi Tomiyama,Takuya Tsuchihashi,Shinichiro Ueda,Yoshinari Uehara,Hidenori Urata,Nobuhito Hirawa +44 more
TL;DR: The story of the life and times of Toshihiko Umemura and his family in the years leading up to and including his death.
Journal ArticleDOI
Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD.
TL;DR: In patients with hypertension starting CAPD therapy, valsartan slows the decline in residual renal function and contributes to maintenance of weekly creatinine clearance and Kt/V (fraction per dialysis), which are the major factors contributing to the mortality and morbidity of CAPD patients.
Journal ArticleDOI
Connective Tissue Growth Factor Expressed in Tubular Epithelium Plays a Pivotal Role in Renal Fibrogenesis
Hirokazu Okada,Tomohiro Kikuta,Tatsuya Kobayashi,Tsutomu Inoue,Yoshihiko Kanno,Masaharu Takigawa,Takeshi Sugaya,Jeffrey B. Kopp,Hiromichi Suzuki +8 more
TL;DR: Tubular CTGF acts as a downstream mediator of the profibrotic effects of TGF-beta1 in the remnant kidney, which is a promising target for antifibrotics drugs designed to treat TGF -beta1-dependent interstitial fibrosis.
Journal ArticleDOI
Effect of Angiotensin Receptor Blockers on Cardiovascular Events in Patients Undergoing Hemodialysis: An Open-Label Randomized Controlled Trial
Hiromichi Suzuki,Yoshihiko Kanno,Soichi Sugahara,Naofumi Ikeda,Junko Shoda,Tsuneo Takenaka,Tsutomu Inoue,Ryuichiro Araki +7 more
TL;DR: Use of an ARB may be effective in reducing nonfatal CVD events in patients undergoing long-term HD, and a larger study is required to confirm these results.
Journal ArticleDOI
A case–control study of calciphylaxis in Japanese end-stage renal disease patients
TL;DR: It was shown that warfarin therapy and lower serum albumin levels are significant and strong risk factors for the development of calciphylaxis in chronic hemodialysis patients in Japan.